Current medical treatment for tuberculosis
BMJ 2002; 325 doi: https://doi.org/10.1136/bmj.325.7375.1282 (Published 30 November 2002) Cite this as: BMJ 2002;325:1282- Edward D Chan, assistant professor of medicine (chane@njc.org),
- Michael D Iseman, professor of medicine
- Department of Medicine, National Jewish Medical and Research Center, Denver, CO 80206, USA
- Correspondence to: E D Chan K613E, National Jewish Medical and Research Center, 1400 Jackson St, Denver, CO 80206, USA
- Accepted 13 September 2002
Instigating effective treatment regimens in a way that improves patient adherence is vital to tackling the global resurgence of tuberculosis
About one third of the world's population has latent tuberculosis, caused by Mycobacterium tuberculosis infection.1 From this pool, roughly 9 million cases of active tuberculosis emerge annually, resulting in 2-3 million deaths. Most new cases occur in the most populated nations—India and China—but the highest rates of disease are seen in sub-Saharan Africa, the Indonesian and Philippine archipelagos, Afghanistan, Bolivia, and Peru. In these regions case rates typically exceed 300 cases per 100 000 per year. 1 2 Although the incidence of tuberculosis declined in North America and western Europe throughout most of the latter half of the 20th century, case rates have increased over the past 10 years mainly because of immigration, HIV/AIDS, and the neglect of tuberculosis control programmes. 3 4 One vital factor in curbing the increase of tuberculosis is the instigation of proper treatment that not only encompasses an effective regimen but also ensures compliance with and response to treatment. This review highlights current treatment recommendations for tuberculosis.
Summary points
Many people worldwide have latent or active tuberculosis, and the number of active cases is expected to increase in the future
The most common cause of treatment failure and acquired drug resistance is non-adherence; predicting non-adherence is highly problematic
Directly observed therapy is the most effective means of combatting non-adherence; intermittent (less than daily) regimens facilitate the therapy
Testing the susceptibility of Mycobacterium tuberculosis to drugs is essential for identifying resistance and tailoring treatment
Managing multidrug resistant tuberculosis is complex and should, when possible, be done in specialised programmes
Sources and selection criteria
We performed a Medline search of the past 10 years using the key words “tuberculosis and treatment or drug therapy” to find pertinent literature. We also searched bibliographies …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.